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Abstract
Rheumatoid arthritis (RA) is three times more common in females than in males, suggesting that
sex may play a role in modifying genetic associations with disease. We have addressed this
hypothesis by performing sex-differentiated and sex-interaction analyses of a genome-wide
association study of RA in a North American population. Our results identify a number of novel
associations that demonstrate strong evidence of association in both sexes combined, with no
evidence of heterogeneity in risk between males and females. However, our analyses also highlight a
number of associations with RA in males or females only. These signals may represent true sex-
specific effects, or may reflect a lack of power to detect association in the smaller sample of males,
and thus warrant further investigation.
Background
The genetic contribution to rheumatoid arthritis (RA)
susceptibility is undisputed, with replicated associations
identifiedwithhaplotypesoftheHLA-DRB1locusandSNPs
in PTPN22 [1,2]. The prevalence of the disease is
approximately 0.8% in Caucasians, but is three times
more common in females than in males [3], suggesting
that sex may play an important role in modifying genetic
associations with RA. The Wellcome Trust Case Control
Consortium (WTCCC) performed genome-wide associa-
tion(GWA)studiesof2,000casesofeachofsevencommon
complex diseases, including RA, with a shared cohort of
3,000controls[4].Insex-differentiatedanalyses,RAwasthe
only disease to demonstrate strong evidence of an effect in
only one of the sexes, a female-specific association with
inter-genic SNPs on chromosome 7q32.
Standard analyses of GWA data for both sexes combined
may lack power to detect a sex-specific effect, particular if
the direction of the association is different in males and
females. Greater power may be achieved by analysis of
males and females separately, although sample sizes
will, of course, be smaller, or through sex-differentiated
analyses in which both sexes are analyzed simulta-
neously, but allowing heterogeneity in male- and
female-specific odds ratios [4].
P a g e1o f4
(page number not for citation purposes)
BioMed  Central
Open AccessHere, we investigate the hypothesis that sex may modify
genetic associations with RA using data from a GWA
study of 868 cases and 1,194 controls of Northern
European ancestry in a North American population,
genotyped using the Illumina HumanHap 550 k
BeadChip. We perform sex-differentiated tests of associa-
tion, and tests of sex interaction, and compare our results
with those obtained from standard analyses for males
and females combined. Our results demonstrate an
association in the major histocompatibility complex
(MHC), independent of the effect of HLA-DRB1 haplo-
types, present in both males and females. We also
highlight a number of apparent sex-specific effects,
which may reflect false positives or a lack of power to
detect association in males.
Methods
Consider a sample of unrelated RA cases and unaffected
controls typed for single-nucleotide polymorphisms
(SNPs) in a GWA study. Let Gi denote the genotype of
the i
th individual at a SNP, coded as 0, 1, and 2 for the
common homozygote, heterozygote, and rare homo-
zygote, respectively. Assuming the effects on risk of the
minor allele at the SNP act in a multiplicative fashion,
we can model the log-odds of disease of the i
th
individual in a logistic regression framework, given by
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In this expression, si denotes the sex of the i
th individual
(coded as 1 for males and 0 for females), and xi denotes
a vector of additional covariate measurements, with
corresponding regression coefficients g and l,r e s p e c -
tively, while the parameter b corresponds to the log-odds
ratio of the minor allele at the SNP. We can perform a
test of association of the SNP with RA, adjusting for the
effects of sex and covariates, xi, by comparing the fit of
the model when b =0t ot h a tw h e nb is unconstrained
via analysis of deviance, having an approximate chi-
squared distribution with one degree of freedom.
To allow for heterogeneity in allelic odds ratios between
males and females, we can model the log-odds of disease
of the i
th individual as
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where the parameter θ corresponds to the SNP-sex
interaction effect. We can then construct a test of SNP-
sex interaction, adjusting for the effects of covariates, xi,
by comparing the fit of the model when θ =0t ot h a t
when θ is constrained via analysis of deviance, having an
approximate chi-squared distribution with one degree of
freedom. Furthermore, we can formulate a two-degree-
of-freedom sex-differentiated test of association of the
SNP with RA via analysis of deviance, by comparing the
f i to ft h em o d e lw h e nb =0a n dθ = 0 to that when both
parameters are unconstrained [5]. When the genetic
effect is different between males and females, this test
provides greater power, in general, for detecting associa-
tion than that based on b = 0 in Model (1).
Results
Genotypes were reported for 531,689 autosomal SNPs to
which stringent quality control (QC) filters were applied.
Atotal of 35,111SNPswereexcludedfromtheanalysison
the basis of low call rate (<97%) and extreme deviation
from Hardy-Weinberg equilibrium (study-wide p <5 . 7×
10
-7 from exact test). To account for population structure
and to minimize the effects of linkage disequilibrium,
identity-by-state (IBS) metrics were calculated for each
pair of individuals for every fifth SNP passing QC filters
with study-wide MAF greater than 1%; the MHC was
excluded to eliminate any bias due to the effect of HLA-
DRB1. Application of multi-dimensional scaling techni-
ques to the resulting matrix of pair-wise IBS statistics
generatedfive axesof geneticvariation associatedwith RA
(p < 0.001) after adjustment for sex as a covariate.
For each SNP passing QC filters, we performed the
following three tests.
￿ Test of association with RA assuming the same
genetic effect for males and females, i.e., b≠0i n
Model (1).
￿ Sex-differentiated test of association with RA
allowing for heterogeneity of genetic effects between
males and females, i.e., b≠0a n d / o rθ≠0i nM o d e l( 2 ) .
￿ Test of interaction with sex, i.e., θ≠0 in Model (2).
In addition to sex, each test was adjusted for five axes of
genetic variation and the number of shared epitope
alleles to account for the effects of HLA-DRB1 haplo-
types. SNPs with MAF less than 5% were excluded from
the analysis because they have low power to detect
modest genetic effects, particularly in sex-differentiated
analyses.
Table 1 presents the lead SNPs in seven regions of strong
association with RA (p <1 0
-5) ,a s s u m i n gt h es a m eg e n e t i c
effect for males and females. Also presented are allelic odds
ratios (and 95% confidence intervals) for both sexes
combined and for males and females separately, and
p-values for the sex-differentiated test of association and
test of sex interaction. The strongest signal of association is
on chromosome 6, within the MHC, indicating an associa-
tion independent of the effects of HLA-DRB1 haplotypes,
>
>
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females. There is also strong association of SNPs in the
previouslyidentifiedTRAF1-C5locusonchromosome9,but
with no apparent evidence of an effect in males. All other
associations identified through this analysis are novel. For
each of these SNPs, allelic odds ratios and confidence
intervals for each sex suggested either no obvious hetero-
geneity in effects between the sexes (signals on chromo-
somes 16 and 20), or female-specific effects with no obvious
association in males (signals on chromosomes 2, 17, and
18). However, there is no evidence of interaction with sex,
indicating that any apparent variation in the strength of the
association are more likely to reflect differences in the male
and female sample sizes.
Table 2 presents the lead SNPs in three regions of strong
association with RA (p <1 0
-5), allowing for hetero-
geneity in genetic effects between males and females in
the sex-differentiated test, not identified in the analysis
of both sexes combined. The region identified on
chromosome 11 showed some evidence of association
in the combined sexes analysis, but demonstrated a
stronger signal in the sex-differentiated test. There is an
apparent effect in both sexes, with the same allele at risk
in males and females. However, the risk appears to be
greater in males than it is in females. The other two
r e g i o n si d e n t i f i e di nt h i sa n a l y s i sd e m o n s t r a t e dn o
evidence of association in the analysis of both sexes
defined because the effects are in different directions in
males and females, in other words the risk allele for one
sex is protective in the other. Table 3 presents the lead
SNPs five regions of stronger sex interaction (p <1 0
-5)
not identified in the combined sexes or sex-differentiated
association analyses. In each of these regions, the signal
is stronger in males than females. In fact, in the region
on chromosome 12 (~127 Mb), there is no association
in females, suggesting a male-specific effect.
Discussion
RA susceptibility has an undisputed genetic component,
and also demonstrates a strong sex effect, with approxi-
mately three times higher prevalence in females than
males. It is also one of the few diseases to have
demonstrated a sex-specific association through GWA
studies [4]. We have performed a range of tests of
association and interaction to investigate the hypothesis
that genetic risk for RA may vary with sex. Signals of
association in the MHC, which are now well established
for RA, demonstrate strong effects in both sexes.
Table 1: Summary of single-SNP tests of association: SNPs demonstrating strong evidence of association (p <1×1 0
-5)o fa s s o c i a t i o n
with RA in the combined sex analysis
SNP Chromosome Location
(Mb)
MAF Combined sexes test Allelic OR
(95% CI)
Sex-
differentiated
test p-value
Sex
interaction
test p-value
p-value Allelic OR
(95% CI)
a
Females Males
rs6737562 2 180.05 0.065 7.11 × 10
-6 2.30 (1.60-3.30) 2.44 (1.61-3.69) 1.77 (0.82-3.82) 2.72 × 10
-5 4.56 × 10
-1
rs17533090 6 32.70 0.189 1.58 × 10
-12 2.38 (1.87-3.02) 2.36 (1.78-3.12) 2.42 (1.51-3.88) 3.85 × 10
-12 7.76 × 10
-1
rs2900180 9 120.79 0.340 3.23 × 10
-8 1.68 (1.40-2.02) 1.87 (1.51-2.33) 1.25 (0.87-1.77) 2.22 × 10
-8 4.86 × 10
-2
rs4924 16 54.95 0.462 7.36 × 10
-7 1.56 (1.31-1.86) 1.47 (1.20-1.80) 1.84 (1.30-2.61) 2.00 × 10
-6 2.80 × 10
-1
rs323413 17 69.24 0.410 6.53 × 10
-6 1.49 (1.25-1.77) 1.59 (1.30-1.94) 1.25 (0.89-1.76) 1.42 × 10
-5 1.98 × 10
-1
rs9949777 18 2.10 0.306 7.57 × 10
-6 1.52 (1.27-1.83) 1.62 (1.31-2.01) 1.31 (0.91-1.90) 1.94 × 10
-5 2.61 × 10
-1
rs1182531 20 57.83 0.190 2.76 × 10
-6 1.76 (1.39-2.22) 1.76 (1.33-2.33) 1.78 (1.15-2.74) 1.23 × 10
-5 8.71 × 10
-1
aAssumes no heterogeneity of allelic odds ratios between males and females.
Table 2: Summary of single-SNP tests of association: SNPs demonstrating strong evidence of association (p <1×1 0
-5)o fa s s o c i a t i o nw i t h
RA in the sex-differentiated analysis, not identified in the combined sex analysis
SNP Chromosome Location
(Mb)
MAF Combined sexes test Allelic OR
(95% CI)
Sex-
differentiated
test p-value
Sex
interaction
test p-value
p-value Allelic OR
(95% CI)
a
Females Males
rs7371994 3 54.57 0.289 5.30 × 10
-1 1.06 (0.88-1.28) 0.76 (0.60-0.95) 2.36 (1.62-3.41) 5.09 × 10
-7 1.68 × 10
-7
rs12412942 10 2.35 0.403 1.91 × 10
-1 1.13 (0.94-1.34) 1.47 (1.19-1.81) 0.53 (0.37-0.76) 1.49 × 10
-6 7.08 × 10
-7
rs17740690 11 122.90 0.065 3.43 × 10
-5 2.19 (1.51-3.17) 1.65 (1.08-2.51) 5.33 (2.40-11.87) 4.63 × 10
-6 1.13 × 10
-2
aAssumes no heterogeneity of allelic odds ratios between males and females.
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associations that demonstrate genetic effects in only one
sex, or reciprocal effects on risk in males and females,
although we do not replicate the female-specific associa-
tion identified by the WTCCC [4]. The main disadvan-
tage of these analyses is the small sample size,
particularly in males. As a result, apparent female-
specific effects may simply reflect a lack of power to
detect association in males, particularly given the lack of
evidence of sex interaction, which would be expected in
the presence of heterogeneity of genetic risk between the
sexes. Furthermore, the apparent male-specific associa-
tions occur at “low-frequency” SNPs (MAF<10%), and
may reflect false positives due to genotyping errors.
These considerations highlight the need for careful
inspection of genotype calling quality, and then replica-
tion in follow-up samples from the same population.
Testing for the presence of sex-specific effects requires
much larger sample sizes because males and females are
analyzed separately, either directly or effectively, through
interaction studies. To increase power, one solution is to
combine results across GWA studies through meta-
analysesofmale-andfemale-specificeffects.Oneobvious
follow-up to the analysis presented here would be to
combine the results of this study with that performed by
the WTCCC [4]. Despite the fact that samples in the two
studieshavebeengenotypedusingdifferenttechnologies,
results can be combined using imputation techniques [6].
Identification of sex-specific effects in this way may help
to explain heterogeneity in results of association signals
across GWA studies if ascertainment schemes vary with
respect to the ratio of males and females sampled, and are
thus extremely important in aiding our understanding of
the biological processes underlying RA.
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-5), not
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MAF Combined sexes test Allelic OR
(95% CI)
Sex-
differentiated
test p-value
Sex
interaction
test p-value
p-value Allelic OR
(95% CI)
Females Males
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-6
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aAssumes no heterogeneity of allelic odds ratios between males and female.
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